ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial
MT Newswires Live
Jun 04
ADC Therapeutics (ADCT) said late Wednesday its phase 3 trial of Zynlonta with rituximab to treat large B-cell lymphoma met the primary endpoint of progression-free survival, with a media PFS of 6.1 months.
Overall response rate achieved was 58.1% while complete response rate stood at 39.5%. There was no detrimental effect to the overall survival secondary efficacy endpoint, according to a statement.
Grade 3 or above treatment emergent adverse events were observed in more than 5% of patients across both arms, with grade 5 event mostly in patients aged 75 and above, the company said.
The company said it plans to carry out a pre-biologics license application meeting in August and preparing for a planned sBLA submission in Q4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.